Deciphera Pharmaceuticals, a Waltham, MA-based clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments, has increased the size of its Series B financing to over $90m.
SV Life Sciences made the additional investment.
In September 2015, the company had announced the initial $75m closing of the Series B, which was led by New Leaf Venture Partners and joined by Deciphera’s existing investors, to fund development of its pipeline of proprietary switch control kinase inhibitors. Concurrent with the financing, Michael Ross Ph.D., Managing Partner at SV Life Sciences, will join Deciphera’s board of directors.
Led by Michael D. Taylor, Ph.D., President and CEO, the company designs small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. The company’s business strategy is to advance its drug candidates for genetically defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs.
The new investment will contribute to the progression of Deciphera’s lead tumor-targeting clinical programs, including Altiratinib and DCC-2618, as well as its immuno-targeted therapies such as DCC-3014 and Rebastanib.